Background. Methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization is a well-established risk factor for subsequent infection and a key event in interindividual transmission. Some studies have showed an association between fluoroquinolones and MRSA colonization or infection. The present study was performed to identify specific risk factors for MRSA acquisition in long-term care facilities (LTCFs).
Staphylococcus aureus is a commensal organism colonizing several sites in the human body, especially the anterior nares. This Gram-positive bacterium is responsible for numerous infections including skin infections, bacteremia or respiratory diseases. Notably, 30%-50% of healthy adults are colonized by S. aureus, and nasal colonization is known to be an important risk factor for subsequent infection [1, 2] , with infection rates higher in carriers than noncarriers [3] [4] [5] and individuals usually being infected with their own carriage isolate [1] . Moreover, the highest risk of methicillin-resistant S. aureus (MRSA) infection occurs shortly after patients become newly colonized [6] .
MRSA was first described in 1961 in England [7] and has since been responsible for numerous hospital and community epidemics worldwide [8] . Despite concerted efforts, control of MRSA diffusion remains elusive in healthcare facilities in many developed countries. MRSA colonization is the major factor leading to the occurrence of infection and results in increased morbidity and mortality rates and hospital costs [9, 10] . Extra in-hospital costs specifically attributable to MRSA infections are estimated to reach 380 million euros annually in Europe [11] . Thus, identification of risk factors for MRSA colonization might help in the development of strategies to prevent MRSA spread in human populations.
Numerous risk factors for MRSA colonization and/or infection have already been identified, including previous hospitalization age, invasive procedure, coma, intensive care unit (ICU) stay, intensity of care, or prior MRSA colonization [12] [13] [14] [15] . Among these factors, the intensity of contacts between healthcare workers and patients might play a crucial role [16] . Use of antibiotics, particularly fluoroquinolones, was associated with increased risk of MRSA colonization in tertiary care hospitals [17] [18] [19] . MRSA diffusion in a population includes 3 individual-level components (acquisition, persistence of colonization, and transmission to another person), and the mechanism behind their association with antibiotic use is poorly understood. Therefore, it is of major importance to investigate whether fluoroquinolone use influences MRSA acquisition, persistence of colonization, or transmission. Herein, we report the results of a study designed to investigate the specific effect of fluoroquinolones on MRSA acquisition.
METHODS

Settings and Study Design
We established a prospective cohort of patients naive for S. aureus colonization to examine risk factors for S. aureus acquisition. The study was conducted in France from January 2008 to October 2010 in 4 neurologic long-term care facilities (LTCFs): Raymond-Poincaré University Hospital, Garches (2 wards), Maritime Hospital, Berck (2 wards), Jacques-Calvé Center, Berck (2 wards), and Sainte-Barbe Center, Fouquières-lès-Lens (4 wards). Hereafter, these LTCFs are respectively referred to as centers 1, 2, 3, and 4. They were chosen because their average duration of patient stay is 3 months, thereby allowing the role of longer patient follow-up in the probability of S. aureus acquisition to be evaluated. Patients hospitalized in LTCFs for neurologic impairment often need extensive care and assistance involving multiple contacts with healthcare workers and antibiotics for urinary infections. In addition, LTCFs may serve as a reservoir for the spread and control of MRSA among hospital providing more-acute care [20] .
Patients were included if they were ≥18 years old, not initially colonized with S. aureus (negative nasal and perineal swab samples at admission), and were hospitalized for a neurologic disorder with an expected length of stay ≥2 months. Immunocompromised patients were excluded. For each patient, nasal colonization status and potential risk factors were collected weekly for 13 weeks after inclusion or until discharge if that occurred earlier. MRSA and/or methicillin-sensitive S. aureus (MSSA) acquisition was defined as the first positive nasal swab sample during follow-up.
Variables associated with S. aureus acquisition were investigated in a nested-matched case-case-control study, which uses 2 separate case-control analyses in a single study [21] . Cases were patients who acquired MRSA (or MSSA). If a patient had acquired both MRSA and MSSA at the first positive nasal swab sample, he or she was considered to be both an MRSA case and an MSSA case in the analyses. Patients whose nasal swab samples were always negative during follow-up served as controls. MRSA and MSSA cases were then compared with different MRSA-and MSSA-negative control groups. This study design allows comparison of the 2 final models and the identification of risk factors specifically associated with MRSA, MSSA, and/or S. aureus acquisition [21] .
Each MRSA case was matched with ≤3 controls and each MSSA case with ≤2 controls by center, date of first nasal swab sample (±6 months), and exposure time. Exposure time for a case was defined from the date of inclusion in the study to the date of S. aureus acquisition [22] . The matched control should have been followed up for at least the same exposure time period. After matching, exposure time for each control was set to equal that of his or her matched case. Matching for exposure time allowed adjustment for confounding by time at risk [23] , and matching for center and date of first nasal swab sample served to limit potential confounding by colonization pressure [24] . Matched controls were randomly selected and could be used in both analyses, because matching procedures for MRSA and MSSA cases were performed separately.
Data Collection
At inclusion, sociodemographic data (sex and age) were collected, as well as clinical characteristics (type of neurologic disorder, diabetes mellitus, intensive care burden at admission, skin lesions at admission) and preadmission history (transfer from another healthcare facility, hospitalization during the preceding year, prior ICU admission, surgery or LTCF stay during the preceding 3 months, and antibiotic use during the past month).
Every week, the following data were prospectively recorded using standardized questionnaires: strict and/or contact isolation, invasive medical device use (catheter, tracheostomy, enteral nutrition, or urination device), aseptic dressing, bodywashing assistance, manual evacuation of fecal impaction, and wound swabbing for S. aureus identification.
Regarding antimicrobial use, daily exposure was recorded either in computerized pharmacy records or in specific standardized questionnaires for the entire institutionalization period. Antimicrobial agents were classified as follows: β-lactams, macrolides, lincosamides and streptogramins, aminoglycosides, fluoroquinolones, other anti-Staphylococcus agents (including glycopeptides, fosfomycin, and linezolid), and others (including tetracyclines, pipemidic acid, polymyxins, fusidic acid, metronidazole, sulfonamides, nitrofuran derivatives, and rifampicin).
For antimicrobial use and variables collected weekly during follow-up, patients who were exposed at least once during their exposure time were considered exposed.
Microbiologic Methods
To assess S. aureus colonization, alginate swabs were rotated around the inside of both nostrils. Swabs were then placed in Stuart's transport medium (Transwab; Medical Wire and Equipment) and kept at room temperature until arrival at the Microbiology Laboratory of Raymond-Poincaré University Hospital. Screening for MRSA and antimicrobial susceptibility testing were performed (see Supplementary Methods). To determine S. aureus clonal diversity, all strains isolated from the first positive nasal swab samples were subjected to spa typing.
Statistical Analyses
Categorical variables were compared using χ 2 or Fisher exact tests; continuous variables were compared with Student t tests. Univariate and multivariable analyses used conditional logistic regression models. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for all variables, and all significant associations were evaluated. All variables with Wald test P < .20 in univariate analyses were included in the multivariable models (hereafter referred to as full models). Backward-stepwise approaches were used to identify independent predictors. Variables were removed one by one manually, starting with the variable with the highest P value, until all remaining variables had statistically significant OR estimates, leading to the final adjusted models. Wald tests were performed to systematically evaluate all pairwise interaction terms in each final model. The HosmerLemeshow goodness-of-fit test was used to assess model fit. Sensitivity analyses were performed after exclusion of patients who acquired S. aureus 1 week after inclusion or patients receiving antibiotic therapy at admission. A further analysis was performed after restricting MRSA cases to those with a fluoroquinolone-resistant phenotype. For all calculations, statistical significance was defined at P < .05 (2 sided). All analyses were performed using Stata software (version 11; StataCorp).
Ethics
An institutional review board (Comité de Protection des Personnes Île-de-France XI) approved the study protocol (reference 07032); no written informed consent was obtained from the patients because the study interventions were standard care. Authorization was also obtained from the Commission nationale de l'informatique et des libertés (French Data Protection Agency; reference 907302).
RESULTS
Study Population
From January 2008 to October 2010, a total of 952 patients were preincluded ( Figure 1 ). Among them, 414 (43.5%) S. aureus carriers at admission were excluded. Colonization pressure was similar across centers (see Supplementary Table 1 ). In total, 451 patients were included from centers 1, 2, 3, and 4, respectively: 159 (35.3%), 59 (13.1%), 150 (33.3%), and 83 (18.4%). The cohort's overall mean age was 51.7 years, 289 patients (64.1%) were male, and 255 (56.5%) were followed up for 13 weeks. During follow-up, 187 patients had ≥1 S. aureus-positive nasal swab sample. The percentages of patients who acquired S. aureus did not differ among centers (P = .37). In total, 76 or 112 patients, respectively, acquired MRSA or MSSA based on their first positive nasal swab sample (1 patient acquired both). The median time from inclusion to MRSA acquisition was 5 weeks (interquartile range, 2-8 weeks) and did not differ significantly (P = .08) from the median time to MSSA acquisition (4 weeks; interquartile range, 2-6 weeks). Nasal swab samples of the remaining 264 patients were negative for S. aureus during follow-up.
Among the 188 S. aureus isolates, 71 (93.4%) of the 76 MRSA strains and 8 (7.1%) of the 112 MSSA strains were fluoroquinolone resistant. The 178 S. aureus isolates (94.7%) represented 69 spa types, and no known spa type could be identified for 6. The 3 predominant spa types were t008 (19.1%), t777 (10.1%), and t002 (6.7%) (Figure 2 ). MRSA strains were less diverse than MSSA strains (21 and 56 spa types, respectively), with 8 shared spa types.
The 76 MRSA cases were matched to 207 MRSA controls, with 55 (72.4%) each matched to 3 controls. The 112 MSSA cases were matched to 208 MSSA controls, with 96 (85.7%) each matched to 2 controls. Among the 264 potential controls, 246 (93.2%) were used for MRSA or MSSA matching, including 170 (69.1%) used for both MRSA and MSSA matching.
Based on exposure time, the protocol called for a total of 2883 samples to be obtained (1 sample per week). Of these, 254 (8.8%) were missing. During this period, the most prescribed antibiotics were ciprofloxacin (70.4%) among fluoroquinolones and amoxicillin/clavulanic acid (33.3%) among β-lactams.
At admission, case-matched controls (n = 246) were comparable to controls (n = 18) not used in the analyses, except for center (P = .01). The latter were also more likely to be men (P = .002) or to have had a previous LTCF stay (P = .01) and were less likely than case-matched controls to have undergone prior surgery (P = .02) or a prior ICU stay (P = .02).
Case-Case-Control Analysis
According to univariate analyses (Table 1) , MRSA acquisition was significantly more frequent in male patients, patients requiring more intensive care at admission, and those hospitalized during the past year or admitted to the ICU during the preceding 3 months, and it was significantly associated with β-lactam or fluoroquinolone use and the need for body-washing assistance during follow-up.
Risk factors were also analyzed for MSSA acquisition. Age distributions differed significantly between MSSA cases and controls, but with no trend according to age. MSSA acquisition was significantly associated with manual evacuation of fecal impaction, body-washing assistance, or use of a urination device. During follow-up, patients whose wounds were swabbed were more likely to acquire MSSA than patients with no wound sampled.
Multivariable analyses retained 3 factors significantly and independently associated with MRSA acquisition: male sex (OR, 2.09; 95% CI, 1.10-3.98), higher intensive care burden at admission (3.24; 1.74-6.04), or fluoroquinolone use (2.17; 1.01-4.67) ( Table 2 ). The independent risk factors for MSSA acquisition were the need for body-washing assistance during follow-up (OR, 2.85; 95% CI, 1.27-6.42) or use of a urination device (1.79; 1.01-3.18). No statistically significant interaction between risk factors was found. Hosmer-Lemeshow goodness-of-fit test results indicated that the final MRSA or MSSA acquisition models reflected the data well (P = .94 and P = .80, respectively).
Similar MRSA and MSSA risk factors were found in multivariable case-control analyses after exclusion of patients who acquired S. aureus 1 week after inclusion or patients receiving antibiotic therapy at admission (Supplementary Table 3 ). In addition, fluoroquinolone use was also significantly associated with fluoroquinolone-resistant MRSA acquisition (Supplementary Table 3 ).
DISCUSSION
Our main objective was to identify risk factors for MRSA acquisition. To the best of our knowledge, this is the first study designed to prospectively evaluate those risk factors in a casecase-control analysis. That study design is considered an effective and more accurate tool to assess risk factors for resistant organisms than a standard case-control design, because it allows simultaneous comparison of the risk factors for the isolation of antibiotic-resistant or antibiotic-susceptible strains [21] .
A key finding was that previous fluoroquinolone use was significantly associated with MRSA but not MSSA acquisition.
That observation strongly suggests that fluoroquinolone use facilitates MRSA acquisition. Previous studies had identified fluoroquinolone use as increasing the risk of MRSA colonization [17, 18] or infection [25] [26] [27] compared with MSSA or absence of S. aureus isolation. A meta-analysis that included 24 320 patients showed that the risk of MRSA colonization or infection increased 3-fold after exposure to fluoroquinolones [28] .
The mechanisms by which fluoroquinolones might influence MRSA acquisition have not yet been fully elucidated. In our study, >90% of MRSA strains and <10% of MSSA strains were fluoroquinolone resistant. Because fluoroquinolones are inactive against most MRSA strains but active against most MSSA strains [29, 30] , they can facilitate undetectable fluoroquinolone-resistant MRSA multiplication after eradicating susceptible rival strains. Moreover, fluoroquinolone resistance may play an intrinsic role. An investigation covering 10 years of hospital MRSA clones showed that dominant clones rarely lost fluoroquinolone resistance, thereby suggesting that this resistance is involved in MRSA selection and survival [29] . In our present study, fluoroquinolone use was significantly associated with fluoroquinolone-resistant MRSA acquisition.
Two mechanisms changing MRSA biologic properties after exposure to fluoroquinolones, might explain how these antibiotics influence MRSA acquisition. First, fluoroquinolone exposure could affect fluoroquinolone-resistant S. aureus adhesion. Two in vitro studies showed that subinhibitory ciprofloxacin levels induced the expression of fibronectin-binding proteins by fluoroquinolone-resistant S. aureus, leading to increased adhesion to fibronectin-coated surfaces [31, 32] . Second, fluoroquinolones might also increase MRSA growth. Thus, half the fluoroquinolone minimal inhibitory concentration increased the proportion of the more resistant subpopulations in heteroresistant S. aureus >10-fold [33] .
We identified 2 additional risk factors for MRSA acquisition: male sex and the need for more intensive care at admission. Male sex had previously been found to be a risk factor [15, 34, 35] , probably because of the higher frequencies of other factors predisposing men rather than women to MRSA acquisition. Moreover, because controls not used in the analyses were more likely to be men than case-matched controls, male sex being a risk factor for MRSA acquisition might partly be an artifact of control selection. More intensive care at admission was previously reported to be associated with acquisition of several antibiotic-resistant organisms, including MRSA [18] . This risk factor may be a marker of disease severity and may reflect the high level of healthcare worker contacts linked to interindividual transmission.
We did not find any concordance among risk factors for MRSA and MSSA acquisition, but factors associated with MRSA (eg, more intensive care at admission) or with MSSA The methods used to investigate MRSA colonization or infection risk factors have differed widely across studies, especially regarding study design (cross-sectional or longitudinal), adjustment for the at-risk period or comorbid conditions, and the control group definition, which could lead to biased evaluation of antibiotic impact. For example, using MSSA-colonized patients as controls could overestimate the association between antibiotic use and MRSA colonization [23] . To date, almost no well-designed epidemiologic studies have ever been undertaken to provide evidence of an association between previous antibiotic exposure and the risk of MRSA acquisition. The casecase-control study design usually uses the same control group for pathogen-resistant and pathogen-sensitive risk-factor analyses [21] . In the present study, we compared MRSA and MSSA cases with different control groups, to match cases and controls according to 3 important confounding variables (center, date of first nasal swab sample, and exposure time), making the controls more representative of the source population from which MRSA and MSSA cases originated. Although the choice of 2 separate control groups may affect comparison of risk factors between the 2 case-control analyses, the fact that our 2 control groups shared numerous patients rendered the results of the 2 analyses much more comparable. Our study had some limitations. First, detection of S. aureus acquisition was based only on standard microbiologic techniques, without recourse to molecular methods (eg, real-time polymerase chain reaction) that can increase detection sensitivity. We were reassured to find t008, t777, and t002 as the most prevalent spa types, which is consistent with the spa types circulating in France and Europe [36, 37] . Moreover, only nasal swab samples were used to determine the presence of S. aureus. Although the combined nasal and skin (axilla and groin) swab samples were shown to be more sensitive than nasal swab samples alone [38] , we decided not to use wound swabbing in the MRSA/MSSA case definitions because we focused on acquisition of colonization, and S. aureus presence in wounds might indicate infection. Furthermore, wounds were not systematically swabbed, so their use could introduce a selection bias, if the swabbed patients were more likely to receive antibiotics. An imperfect S. aureus detection sensitivity from perineal and nasal swab samples at inclusion could result in including falsenegative patients, thus biasing our cohort selection. Similarly, a missing or false-negative nasal swab sample during follow-up could yield misclassification of cases as controls, making them more alike and thus underestimating the ORs. Nevertheless, after exclusion of patients who acquired S. aureus 1 week after study inclusion or those receiving antibiotic therapy at admission, multivariable analyses yielded similar results, thereby reinforcing our findings.
Second, colonization pressure was not evaluated and, therefore, could not be used to adjust our models for the MRSA and MSSA burden. However, we chose to match by center and date of first nasal swab sample to limit potential confounding by colonization pressure.
Third, our findings in LTCFs might not be generalizable to all hospital settings. However, the association we found between fluoroquinolone use and MRSA acquisition expands previous knowledge on risk factors for MRSA colonization/infection in tertiary care hospitals [17] [18] [19] [25] [26] [27] , reinforcing the notion that antibiotic stewardship is essential, whatever the setting. Antibiotic use being rather intensive and inappropriate in LTCFs [39] , it may differ from that in tertiary care hospitals.
In conclusion, S. aureus cross-transmission in LTCFs can be controlled by improving hygiene, particularly hand washing. Notably, the effect of fluoroquinolones on MRSA acquisition represent another determinant of MRSA diffusion. Nevertheless, their effect on the other stages of MRSA diffusion ( persistent colonization and transmission) remains to be investigated. Our findings should encourage reconsideration of the importance of cautious fluoroquinolone use.
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